Please login to the form below

Not currently logged in
Email:
Password:

UK diabetes spend to reach £16.9bn by 2035

In 25 years 17 per cent of NHS budget to go on the condition
By 2035 the NHS will increase its spending on diabetes from £9.8bn to £16.9bn, according to a new report published in the journal Diabetic Medicine.

Authored by York Health Economic Consortium and in partnership with Diabetes UK, the diabetes research charity JDRF and Sanofi Diabetes, the Impact Diabetes report also suggests that the cost of treating diabetes complications will double, from £7.7bn to 13.5bn during this period.

According to the report, 79 per cent of current NHS diabetes spending goes on complications, however, investing in 'checks and services' could help reduce this cost.

“This report shows that without urgent action, the already huge sums of money being spent on treating diabetes will rise to unsustainable levels that threaten to bankrupt the NHS,” said Barbara Young, chief executive of Diabetes UK.

“But the most shocking part of this report is the finding that almost four-fifths of the NHS diabetes spending goes on treating complications that in many cases could have been prevented.

“The failure to do more to prevent these complications is both a tragedy for the people involved and a damning indictment of the failure to implement the clear and recommended solutions. Unless the Government and the NHS start to show real leadership on this issue, this unfolding public health disaster will only get worse”.

JDRF commended the report for having separately listed the causes and costs of Type 1 diabetes, against the challenges and costs of Type 2. They also called for more research to be done to assist the economic impact on families, the NHS and the economy.

Sanofi, who earlier this year invested $3.1m into diabetes research with the University of California, have said that they plan to continue examining the cost impact of adopting NICE guidelines across the UK, which aims to use effective management in order to reduce the cost burden of diabetes.

8th August 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HealthCare21 Communications

HealthCare21 is an independent strategic medical communications company. We support pharmaceutical companies active in specialty therapeutic areas, through the development...

Latest intelligence

Online Physician Communities
M3 improves personalisation of pharma engagement with doctors
Launches new messaging service on Doctors.net.uk...
Digital Futures 2014 slide deck
Full slides, including survey data, from PMLiVE's digital pharma marketing online event...
The Chinese diabetes challenge
Marketing, communications and commercial relationships in China are full of pitfalls for the unwary, but not without great potential ...